Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
After two Asian trial flops, Sumitomo Dainippon Pharma said in January that it finally hit PIII goals with its blockbuster atypical antipsychotic Latuda (lurasidone) to yield meaningful results for filing in Japan. Then on July 31, the company made it…
To read the full story
Related Article
- Latuda to Finally Hit Japan Market on June 11
June 5, 2020
- Latuda Succeeds in PIII Schizophrenia Study, Japan NDA Submission Planned by September
January 11, 2019
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
October 29, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- Sumitomo Dainippon Aims to File Lurasidone in Japan in FY2015 following Favorable Asian PIII Study Results
December 26, 2014
BUSINESS
- Kyowa Kirin, Kura Form Global Collab on Leukemia Drug
November 22, 2024
- Alloy Inks Cell Therapy Deal with Takeda, Japan Outpost to Launch by Month-End
November 22, 2024
- Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
- Tepezza, Trodelvy, and More Drugs Now Available in Japan; Kisunla Due Out on Nov. 26
November 21, 2024
- MM Drug Talquetamab Filed in Japan: J&J
November 21, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…